Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9693742 | 0.81 | TSHR (0.45) | EDNRARAB9AKDM4ETSHRL3MBTL1 | |
| SCHEMBL17440438 | 0.80 | KDM4E (0.41) | EDNRARAB9AKDM4ETSHRL3MBTL1 | |
| SCHEMBL4849720 | 0.80 | EDNRA (0.46) | EDNRARAB9AKDM4ETSHRL3MBTL1 | |
| SCHEMBL719825 | 0.77 | CYP2C19 (0.47) | RAB9AKDM4ETSHRL3MBTL1HPGD | |
| SCHEMBL4623864 | 0.74 | GRN (0.46) | RAB9ATSHRHPGDHSD17B10NPC1 | |
| SCHEMBL14015884 | 0.74 | KDM4E (0.45) | RAB9AKDM4ETSHRL3MBTL1HPGD | |
| SCHEMBL6647556 | 0.73 | MAPK14 (0.58) | RAB9AKDM4ETSHRL3MBTL1NPC1 | |
| SCHEMBL13624583 | 0.72 | BRD4 (0.40) | RAB9AKDM4ETSHRL3MBTL1HPGD | |
| SCHEMBL442779 | 0.72 | MCL1 (0.60) | EDNRARAB9AKDM4ETSHRL3MBTL1 | |
| SCHEMBL19233637 | 0.72 | LMNA (0.47) | RAB9AKDM4ETSHRL3MBTL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563784-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-21 | — | — | US | claimed |
| EP-1713790-A2 | METHOD OF PREPARATION OF BENZOFURAN-2-CARBOXYLIC ACID (S)-3-METHYL-1- ((4S, 7R)-7METHYL-3-OXO-1-(PYRIDINE-2-SULFONYL)-AZ EPAN-4-YLCARBAMOYL-BUTYL)-AMIDE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-25 | — | — | EP | claimed |
| US-20060194787-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | claimed |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | claimed |
| EP-1307203-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-08-17 | — | — | EP | claimed |
| WO-2005069981-A2 | METHOD OF PREPARATION OF BENZOFURAN-2-CARBOXYLIC ACID {(S)-3-METHYL-1-[(4S, 7R)-7METHYL-3-OXO-1-(PYRIDINE-2-SULFONYL)-AZEPAN-4-YLCARBAMOYL]-BUTYL}-AMIDE | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-04 | — | — | WO | claimed |
| US-20040229863-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-11-18 | — | — | US | claimed |
| US-20040044201-A1 | Protease inhibitors | GLAXOSMITHKLINE LLC | 2004-03-04 | — | — | US | claimed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | claimed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | claimed |
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | claimed |
| CN-1431904-A | Protease inhitors | SMITHKLINE BEECHAM CO (US) | 2003-07-23 | — | — | CN | claimed |
| US-20030114437-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-06-19 | — | — | US | claimed |
| EP-1278502-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-05-21 | — | — | EP | claimed |
| EP-1307203-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-07 | — | — | EP | claimed |
| CN-1416346-A | Peotease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2003-05-07 | — | — | CN | claimed |
| EP-1278502-A2 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-01-29 | — | — | EP | claimed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | claimed |
| WO-2001089451-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | claimed |
| WO-2001070232-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114437-A1 | Protease inhibitors | CTSS, CTSE, CTSF | EDNRA 1369/4885RAB9A 1456/4885KDM4E 2876/4885 |
| US-20030225061-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | EDNRA 3308/4885RAB9A 1322/4885KDM4E 917/4885 |
| US-20060194787-A1 | Protease inhibitors | CTSK, CTSL, CTSZ | EDNRA 3914/4885RAB9A 954/4885KDM4E 1163/4885 |
| US-20040044201-A1 | Protease inhibitors | CTSK, CTSE, CTSZ | EDNRA 4041/4885RAB9A 1258/4885KDM4E 763/4885 |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | CTSK, CTSZ, CTSE | EDNRA 3703/4885RAB9A 2214/4885KDM4E 875/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | EDNRA 3308/4885RAB9A 1322/4885KDM4E 917/4885 |
| US-20040229863-A1 | Protease inhibitors | CTSS, CTSE, CTSF | EDNRA 1369/4885RAB9A 1456/4885KDM4E 2876/4885 |
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | EDNRA 3308/4885RAB9A 1322/4885KDM4E 917/4885 |
| US-20030144175-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | EDNRA 3308/4885RAB9A 1322/4885KDM4E 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.